ArticleCell stem cell2015
Maintaining What Is Already There: Strategies to Rectify HSC Transplantation Dilemmas.
Article in Cell stem cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Acellular, bioresorbable, ultra-purified alginate gel implantation for intervertebral disc herniation: Phase 1/2, open-label, non-randomized clinical trials.Nature communications · 2025Trial
- Article
- Review
- Fibrocartilage Stem Cells in the Temporomandibular Joint: Insights From Animal and Human Studies.Frontiers in cell and developmental biology · 2021Review
- Coinhibition of activated p38 MAPKα and mTORC1 potentiates stemness maintenance of HSCs from SR1-expanded human cord blood CD34Stem cells translational medicine · 2020Article
- An acellular bioresorbable ultra-purified alginate gel promotes intervertebral disc repair: A preclinical proof-of-concept study.EBioMedicine · 2018Article
- Exploiting endogenous fibrocartilage stem cells to regenerate cartilage and repair joint injury.Nature communications · 2016Article
- Multilineage readout after HSC expansion - erythrocytes matter.Cell cycle (Georgetown, Tex.) · 2016Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell (HSC) transplantation remains the only cure for various hematological diseases, but low HSC numbers in many donor samples are a critical problem preventing their clinical use. Now in Nature and Cell, two creative strategies to rescue and improve pre-existing engraftment potential are presented.
Indexed as
Identifiers
26340525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.